Key Points
- Director Matthew Klein sold 16,000 shares of ClearPoint Neuro on May 21 at an average price of $11.59, worth about $185,440. After the sale, he still held 46,935 shares.
- ClearPoint Neuro recently reported quarterly earnings of -$0.32 EPS, missing analyst expectations, though revenue of $12.13 million came in slightly above forecasts. The company continues to show negative profitability metrics.
- Analyst sentiment is mixed but leans cautious: the stock has a consensus rating of Hold with a $18.00 price target, while institutions like Millennium Management and Goldman Sachs increased their holdings in recent quarters.
ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) Director Matthew Klein sold 16,000 shares of the company's stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $11.59, for a total transaction of $185,440.00. Following the transaction, the director owned 46,935 shares in the company, valued at $543,976.65. This represents a 25.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
ClearPoint Neuro Price Performance
CLPT opened at $11.82 on Wednesday. The stock has a market capitalization of $354.48 million, a P/E ratio of -11.70 and a beta of 1.29. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79. The company's 50-day simple moving average is $10.57 and its two-hundred day simple moving average is $12.67. ClearPoint Neuro, Inc. has a 52-week low of $8.27 and a 52-week high of $30.10.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The business had revenue of $12.13 million for the quarter, compared to analysts' expectations of $11.97 million. As a group, analysts predict that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in CLPT. Millennium Management LLC lifted its position in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock valued at $8,813,000 after buying an additional 452,043 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock valued at $3,066,000 after buying an additional 127,823 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of ClearPoint Neuro by 35.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,790 shares of the company's stock valued at $392,000 after buying an additional 8,581 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of ClearPoint Neuro during the 2nd quarter valued at about $35,000. Finally, Rhumbline Advisers purchased a new position in shares of ClearPoint Neuro during the 2nd quarter valued at about $450,000. 30.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Stifel Nicolaus assumed coverage on shares of ClearPoint Neuro in a research report on Friday, May 8th. They set a "buy" rating and a $16.00 price target for the company. B. Riley Financial upped their price target on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ClearPoint Neuro has a consensus rating of "Hold" and a consensus price target of $18.00.
View Our Latest Research Report on CLPT
ClearPoint Neuro Company Profile
(
Get Free Report)
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company's flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
